Tharimmune Inc (THAR)

[TheFinalCD]

$THAR S-1 OFFERING PRICED https://www.accesswire.com/viewarticle.aspx?id=810583

https://finviz.com/quote.ashx?t=THAR&ty=c&ta=1&p=d

$1.00 OFFER
https://dilutiontracker.com/app/search/THAR

Finding appropriate biomarkers for our potential drug candidates could limit our commercialization prospects and cause our losses to continue.



Any biomarker discovery or drug development that we are conducting may not be successful in identifying biomarkers that have commercial value for our products or therapeutic utility. Platforms may initially show promise in identifying potential biomarkers for our drug candidates, yet fail to stratify patients for clinical development or commercialization for a number of reasons, including, but not limited to:



? research programs to identify new biomarkers will require substantial technical, financial and human resources, and we may be unsuccessful in our efforts to identify biomarkers. If we are unable to identify suitable biomarkers for pre-clinical and clinical development, our ability to stratify patients could be compromised, which could result in significant harm to our financial position and adversely impact our stock price;